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Background: Although the presence of late gadolinium enhancement (LGE) using cardiovascular magnetic
resonance imaging (CMR) is a significant discriminator of events in patients with suspected myocarditis, no data are
available on the optimal LGE quantification method.
Methods: Six hundred seventy consecutive patients (48 ± 16 years, 59% male) with suspected myocarditis were
enrolled between 2002 and 2015. We performed LGE quantitation using seven different signal intensity thresholding
methods based either on 2, 3, 4, 5, 6, 7 standard deviations (SD) above remote myocardium or full width at half
maximum (FWHM). In addition, a LGE visual presence score (LGE-VPS) (LGE present/absent in each segment) was
assessed. For each of these methods, the strength of association of LGE results with major adverse cardiac events (MACE)
was determined. Inter-and intra-rater variability using intraclass-correlation coefficient (ICC) was performed for all methods.
Results: Ninety-eight (15%) patients experienced a MACE at a medium follow-up of 4.7 years. LGE quantification by
FWHM, 2- and 3-SD demonstrated univariable association with MACE (hazard ratio [HR] 1.05, 95% confidence interval [CI]:
1.02–1.08, p = 0.001; HR 1.02, 95%CI:1.00–1.04; p = 0.001; HR 1.02, 95%CI: 1.00–1.05, p = 0.035, respectively), whereas 4-SD
through 7-SD methods did not reach significant association. LGE-VPS also demonstrated association with MACE (HR 1.09,
95%CI: 1.04–1.15, p < 0.001). In the multivariable model, FWHM, 2-SD methods, and LGE-VPS each demonstrated
significant association with MACE adjusted to age, sex, BMI and LVEF (adjusted HR of 1.04, 1.02, and 1.07; p = 0.009,
p = 0.035; and p = 0.005, respectively). In these, FWHM and LGE-VPS had the highest degrees of inter and intra-rater
reproducibility based on their high ICC values.
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Conclusions: FWHM is the optimal semi-automated quantification method in risk-stratifying patients with suspected
myocarditis, demonstrating the strongest association with MACE and the highest technical consistency. Visual
LGE scoring is a reliable alternative method and is associated with a comparable association with MACE and
reproducibility in these patients.
Trial registration number: NCT03470571. Registered 13th March 2018. Retrospectively registered.
Keywords: Myocarditis, Outcome, MACE, CMR, Cardiovascular magnetic resonance imaging, Quantification
method, Full width half maximum, FWHM, Standard deviation, SDBackground
Myocarditis is a frequent cause of dilated cardiomyop-
athy [1]. Myocarditis has diverse pattern of clinical signs
and symptoms at presentations [2, 3] and its diagnosis
may be challenging, as the sensitivity of the main diag-
nostic tools may vary greatly [1, 4, 5]. Cardiovascular
magnetic resonance imaging (CMR) has become the
primary imaging tool for establishing the diagnosis by
the use of late gadolinium enhancement (LGE) imaging
[2, 5–8]. We recently showed an incremental prognostic
value of LGE in risk stratifying patients with suspected
myocarditis [9]. However, an optimal method of LGE
quantification in patients with suspected myocarditis is
currently unknown. Better characterization of LGE pat-
tern is important given that the heterogeneity in presence,
localization and intensity of LGE extent in myocarditis [6]
and that may improve clinical decisions. We therefore
sought to compare LGE quantification techniques includ-
ing thresholding by 2, 3, 4, 5, 6 or 7 standard deviations
(SDs) above remote myocardium, the full width at half
maximum (FWHM) technique, and visual quantification,
as well as their respective association with clinical out-
come in a post-hoc analysis of patients with suspected
myocarditis [9].Methods
Study population
The study included consecutive patients referred for
CMR at our center for “suspected myocarditis” as the
primary clinical question between December 2002 and
December 2015 [9]. In real-world clinical practice, diag-
nosis of myocarditis is challenged by a lack of reference
standards including the use of noninvasive measures,
serum biomarkers, and even tissue pathology from inva-
sive biopsies [10]. We included consecutive patients with
suspected myocarditis raised as a referral indication with
presenting signs/symptoms from either one of 2 groups:
1) acute chest pain syndromes with symptom onset < 2
weeks before CMR; 2) subacute (onset ≥2 weeks) of
dyspnea, signs of left ventricular (LV) dysfunction, or
ventricular arrhythmias syncopal spells or abnormal
electrocardiogram (ECG). Exclusion criteria included:
1) any evidence of coronary artery disease (CAD) byeither previous documented medical history, any previ-
ous or newly detected relevant CAD in non-invasive or
invasive imaging or subendocardial LGE consistent of
CAD in a territory subtended by a coronary vessel 2)
any evidence of hypertrophic cardiomyopathy, arrhyth-
mogenic right ventricular (RV) cardiomyopathy, cardiac
sarcoidosis, or cardiac amyloidosis; and 3) any evidence
of Takotsubo cardiomyopathy, constrictive pericarditis,
Loeffler endocarditis, ventricular noncompaction, car-
diac tumor, pulmonary embolism, or severe valvular
disease. Seven hundred forty-four patients were in-
cluded. Fifty-nine (7.9%) patients were excluded based
on CMR findings consistent with: myocardial infarction
(N = 35), biopsy-proven cardiac amyloidosis (N = 6),
ventricular non-compaction (N = 3), Takotsubo cardio-
myopathy (N = 4), constrictive pericarditis (N = 2), car-
diac sarcoidosis (N = 2), Loeffler endocarditis (N = 2),
and 1 each for arrhythmogenic cardiomyopathy, hyper-
trophic cardiomyopathy, pulmonary embolism, cardiac
tumor, and severe valvular disease. Fifteen patients were
excluded due to technical reasons (claustrophobia with
incomplete CMR scans or non-diagnostic LGE images)
[9]. Takotsubo cardiomyopathy was defined as previously
published with apical ballooning [11], elevated troponin, ab-
sence of CMR features suggesting of myocarditis (absence
of LGE) and absence of coronary artery disease. Clinical
data including medication, laboratory tests including car-
diac biomarkers, and ECG before CMR scanning were ana-
lyzed. Abnormal troponin I was defined < 0.10 ng/mL and
troponin T < 14 ng/l. Normal values of creatine phosphoki-
nase (CPK) were < 145U/l in women and < 170U/l in men.
Clinical data, cardiac biomarkers and ECG were analyzed at
baseline by a cardiologist.CMR imaging protocol and image post-processing
The CMR systems included a 3T (Tim Trio, Siemens
Healthineers, Erlangen, Germany) and a 1.5 T (Aera,
Siemens Healthineers). All patients underwent cine bal-
anced steady-state free precession (bSSFP) imaging and
an LGE imaging protocol (TR, 4.8ms; TE, 1.3ms; inversion
time, 200 to 300ms), using a segmented inversion-recovery
pulse sequence starting 10 to 15min after a weight-based
injection (cumulative dose 0.15mmol/Kg) of gadolinium
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HealthCare Pharmaceuticals Inc., Berlin, Germany). In
122 (21%) patients, Multihance (Bracco Diagnostic,
Milan, Italy) was used instead of Magnevist. In patients
with an estimated glomerular filtration rate (eGFR) < 60
mL/min/1.73m2, contrast dose was restricted to 0.1
mmol/kg or 20 ml, whichever was lower in volume in
compliance with our institutional policy [12]. A com-
mercially available software (MASS v15, Medis, Leiden,
The Netherlands) was used to post-process and quan-
tify all CMR images.
LGE quantification
Semi-automated quantification was performed as fol-
lows: Epicardial and endocardial LV contours were care-
fully placed manually on all LGE images. The remote
non-LGE reference region of each LGE slice was placed
adjacent to the region of LGE so that the reference
region is at approximate equal distance from the anter-
ior receiver coils. Therefore, we believe this method
minimizes any modifying effect from LGE location to ro-
bustness of the LGE quantitation. LGE mass was then
quantified by semi-automatic methods using a signal in-
tensity threshold of > 2,3,4,5,6,7-SD, respectively above a
reference region of remote myocardium (adjacent to the
region of LGE and approximately equal in distance to
anterior receiver coils) in the same slice, and using
regions defined as above 50% of maximal signal in-
tensity of the enhanced area for the FWHM approachFig. 1 Example of the different late gadolinium enhancement (LGE) quanti
with endocardium and epicardium is demarcated, b 2-SD (LGE: 28.9 g, 24.9
(12.2 g, 10.5%); e 5-SD (8.1g, 7.0%); f 6-SD (5.2 g, 4.5%); g 7-SD (3.3 g, 2.9%);
116 g. The fibrosis is outlined in yellow. For 2 to 7-SD a region of interest
arrow/yellow contour). For FWHM, an automated ROI 2 is identified in the
midventricular slice is represented, however, total LGE quantification includes(see Fig. 1) [13, 14]. Artifacts were manually erased. In
all methods LGE mass (in grams), was then expressed as a
percentage of total LV mass determined by bSSFP cine im-
ages [15]. LGE extent was also determined visually by the
17 segments model by using two different scores: [1] LGE
being present or not in the segment defined the visual
presence score (LGE-VPS) (maximum score 17), and [2]
the visual transmurality score (LGE-VTS) summed the
transmural extent of LGE per segment, assessed by a
five-point scale (0 = no LGE, 1 = < 25% transmurality,
2 = 26–50% transmurality, 3 = 51–75% transmurality,
4 = 76–100% transmurality) (maximum score 68). VPS
sizing aimed to include any abnormal enhancement on
LGE images including regions of intermediate signal
intensity. LGE image quality was graded as: 1 = poor
image quality, 2 = fair image quality, 3 = good image
quality, and 4 = excellent image quality. LGE images
were evaluated by the consensus of two American College
of Cardiology Core Cardiovascular Training Statement
(COCATS) level III experienced readers (CG and RYK)
and inter-rater reproducibility testing was performed by
an independent experienced CMR investigator (KK).
Follow-up of clinical endpoints
We reviewed all available electronic medical records in-
cluding mortality status from Social Security Death
Index for all subjects. Subjects were then sent a stan-
dardized checklist-based patient-questionnaire by mail
and/or followed-up by a scripted telephone interviewfication methods in a patient with suspected myocarditis. a LGE-image
% of total left ventricular (LV) mass); c 3-SD (19.4g, 16.8%); d 4-SD
h full width half maximum (FWHM) (14.7 g, 12.6%). Total LV mass was
(ROI) 1 is identified in the reference remote myocardium (yellow
affected myocardium (pink arrow/pink contour). Of note, only the
mass and percentage of the entire left ventricle. SD = standard deviation
Table 1 Baseline Characteristics
All patients
(n = 670)
Baseline
Age (year) 47.8 ± 16.0
Female sex 278 (41%)
BMI, kg/m2 27.8 ± 6.3
Acuteness of Presentation
Acute chest pain syndromes (< 2 weeks) 350 (52%)
Subacute presentation (> 2 weeks)
with dyspnea or left ventricular dysfunction
201 (30%)
Subacute presentation (> 2 weeks)
with ventricular arrhythmias, syncopal
spells or abnormal ECG
119 (18%)
Prior Cardiovascular History
Hypertension 181 (27%)
Tobacco 76 (11%)
Diabetes 60 (9%)
Dyslipidemia 138 (21%)
Medications
Aspirin 186 (28%)
ACE inhibitors 229 (35%)
Beta-blockers 266 (40%)
Diuretics 135 (21%)
Statins 142 (22%)
Insulin 23 (4%)
ECG
Abnormal ECG 278 (42%)
Laboratory Testing’s
Troponin abnormal 170 (63%)
Creatine-kinase abnormal 70 (40%)
White blood cell count abnormal 105 (35%)
ACE angiotensin converting enzyme inhibitor, BMI body mass index,
ECG electrocardiogram
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Subjects were given an option to refuse to be contacted by
telephone whether or not they decided to return the ques-
tionnaire by mail. Subjects who we were not able to estab-
lish contact for at least 6months after the CMR were
considered lost to follow-up. We defined the primary end-
point being a composite major adverse cardiac events
(MACE): a) all-cause death, heart failure decompensation
requiring hospital admission as defined in prior trials
[16, 17], heart transplantation, documented sustained
ventricular arrhythmia (> 30 s), recurrent acute myocardi-
tis based on clinical biomarkers and CMR Lake-Louise
definition [6]. Time-to-MACE was determined from the
CMR study date to the occurrence of the first MACE or
censorship at end of the follow-up period. All study proce-
dures were reviewed and approved by our Institutional
Review Board in accordance with institutional guidelines.
Statistical analysis
Categorical variables were presented as percentages of
the entire cohort or as percentage of the corresponding
group if relevant data were missing. Continuous variables
were expressed as mean ± standard deviation or as median
values with interquartile range [IQR] depending on nor-
mality of distributions. Categorical variables were com-
pared using the Chi2 or Fisher exact test in low field
numbers, whereas comparisons for continuous data were
performed using 2-sample Student t-test or Wilcoxon
rank-sum test, when appropriate. A two-sided p-value of <
0.05 was deemed significant. Univariable associations with
MACE and chi-square were determined by Cox propor-
tional hazards regression. Multivariable (simultaneous
entry, i.e. enter method) associations of risk covariates with
MACE were determined by Cox proportional hazards re-
gression. Multivariable models were built by including
LGE extent from the various quantification methods and
clinical variables in order to test for the prognostic associ-
ation of LGE extent incremental to common clinical risk
markers. For each multivariable model, the assumption of
proportional hazards was checked and confirmed valid.
For inter-rater and intra-rater reliability analyses, we ran-
domly selected 20 patients with LGE presence and com-
pared the measurement of LGE extent using all 7
quantitative methods (2-SD through 7-SD, FWHM) by two
independent readers. Each CMR scan was independently
contoured by the 2 readers and automated region of refer-
ence (ROI) was selected to generate the LGE extents for
comparison. Furthermore, the LGE-VPS and LGE-VTS
visual scores by two independent readers were assessed
for Intra- and inter-reader agreement using intraclass-
correlation coefficient (ICC). SAS (version 9.4, SAS
Institute Inc., Cary, USA) and SPSS 22.0 (International
Business Machines Corporation, Armonk, New York,
USA) software packages were used for analysis.Results
A total of 670 patients represented our study group with
2 (0.3%) patients lost to follow-up and a median
follow-up of 4.7 [IQR 2.3–7.3] years. Mean age was 48 ±
16 years and 392 (59%) patients were male. CMR studies
were performed using a 3 T scanner in 535 (80%) pa-
tients and the remaining using a 1.5 T scanner. 350
(52%) patients presented with acute chest pain syn-
dromes (< 2 weeks) and the remaining 320 (48%) were
subacute presentations (> 2 weeks). LGE was present in
294 (44%) patients. Among these 169 (57%) were in the
acute presentation group and 125 (43%) were in the sub-
acute presentation group. Baseline and CMR characteris-
tics are depicted in Tables 1 and 2. In 24 (3.5%) patients,
LGE image quality was poor, in 92 (13.7%) image quality
was fair, in 356 (53.1% image quality was good and in
Table 2 CMR Baseline Characteristics
All patients
(n = 670)
LVEF (%) 50 ± 15
LVEDVi (ml/m2) 98 ± 33
LVESVi (ml/m2) 53 ± 34
LV mass index (g/m2) 61 ± 17
RVEF (%) 49 ± 11
RVEDVi (ml/m2) 80 ± 21
RVESVi (ml/m2) 42 ± 17
Pericardial effusion 169 (25%)
T2- weighted imaging (SIR ≥2) 124 (27%)
LGE presence 292 (44%)
LGE-VPS 1.7 ± 3.4
LGE-VTS 4.2 ± 8.9
LGE mass (g)
- 2-SD 5.5 ± 10.6
- 3-SD 3.7 ± 7.7
- 4-SD 2.6 ± 5.8
- 5-SD 1.7 ± 4.1
- 6-SD 1.2 ± 3.2
- 7-SD 0.8 ± 2.4
- FWHM 2.7 ± 5.3
LGE mass (%)
- 2-SD 4.7 ± 8.8
- 3-SD 3.1 ± 6.5
- 4-SD 2.2 ± 4.9
- 5-SD 1.5 ± 3.5
- 6-SD 1.0 ± 2.7
- 7-SD 0.7 ± 2.1
- FWHM 2.2 ± 4.5
CMR cardiovascular magnetic resonance imaging, LVEF left ventricular ejection
fraction, LVEDVi left ventricular end diastolic volume indexed, LVESVi left
ventricular end systolic volume index, RVEF right ventricular ejection fraction,
RVEDVi right ventricular end-diastolic volume index, RVESVi right ventricular
end-systolic volume index, LGE late gadolinium enhancement,. SIR signal
intensity ratio (ratio of signal in myocardium divided by signal in skeletal
muscle), VPS visual presence score, VTS visual transmurality score, FWHM full
width half maximum;
T2 weighted imaging is available in 465 patients
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presented in Fig. 2.
LGE extent and outcome
Ninety-eight (15%) patients showed a MACE at follow-up.
MACE included 29 deaths (4%), 38 heart failure hospitali-
zations (6%), 22 sustained ventricular arrhythmias (3%), 7
recurrent myocarditis (1%), and 2 cases of heart trans-
plantation (0.3%). As depicted in Fig. 3, LGE (%) quantifi-
cation by 2-, 3-SD or FWHM demonstrated robust
prognostic association with MACE, whereas 4-SD through7-SD showed non-significant prognostic association. Asso-
ciation of clinical parameter, CMR characteristics and
different LGE extent (g) with outcome are depicted in
Table 3.
By univariable analysis of LGE-VPS, a 9% increase in
MACE hazards was observed per each abnormal LGE seg-
ment (HR 1.09, 95%CI: 1.04–1.15, p < 0.001). LGE-VTS
showed a HR of 1.02 (95%CI: 1.01–1.04, p < 0.001). Age,
female sex and body mass index (BMI) were associated
with MACE (HR 1.03, 95%CI: 1.01–1.04, p < 0.001; HR
1.60, 95%CI: 1.07–2.38, p = 0.021 and HR 1.05, 95%CI
1.02–1.08, p = 0.001, respectively). When re-analyses were
performed for death, heart failure hospitalization, and a
need for heart transplant, LGE presence maintained ro-
bust association with these composite events, whereas
LGE VPS and VTS demonstrated trend associations.
In the multivariable models (including age, sex, body
mass index (BMI), LV ejection fraction (LVEF), LGE ex-
tent (%) using the FWHM method was an incremental
outcome predictor (see Table 4). This also held true,
when adding either the variable acute/subacute presenta-
tion to the multivariable model (LGE FWHM HR: 1.04,
95%CI: 1.00–1.08, p = 0.021) or the difference magnet
strengths (1.5 and 3.0) (LGE FWHM HR 1.04, 95%CI
1.01–1.08, p = 0.016). Similarly, LGE extent (%) using the
2-SD method was independently associated with outcome
(see Table 4 model 2), whereas 3-SD to 7-SD methods
were not independent outcome predictors (all p =NS).
Using visual scores, LGE-VPS was an independent pre-
dictor for outcome (see Table 4, model 5). This also held
true when adding the variable acute/subacute presentation
in the multivariable model to LGE-VPS (LGE-VPS HR:
1.06 (95%CI: 1.01–1.12, p = 0.015).
When adjusted to age, sex, BMI and LVEF, LGE-VPS
maintained its strong association with MACE. For
methods that quantified LGE size, LGE (%) by FWHM
maintained robust adjusted association with MACE. In
the multivariable model (including age, sex, BMI, LVEF;
LGE extent and pericardial effusion), LGE extent (%,
FWHM method) maintain significant adjusted association
with MACE (HR 1.04. 95%CI: 1.01–1.08, p = 0.017),
whereas pericardial effusion did not maintain its signifi-
cance in the model (HR 1.5, 95%CI 0.96–2.3, p = 0.073).
LGE image quality did not have an impact on the predict-
ive value of LGE quantification methods.
In the quantification methods significantly associated
with outcome, excellent intra-rater and inter-rater repro-
ducibility was achieved in visual scoring (LGE-VPS,
LGE-VTS) and FHWM (p < 0.001) (see Fig. 4).
Discussion
Our current study represents a systematic assess-
ment of different semi-automated quantification
methods of LGE extent in a large cohort of patients
Fig. 2 Difference in LGE mass (%) between different semi-automated quantification methods in LGE positive cases are displayed. Comparing the
different semi-quantitative LGE quantification methods, the greatest amount of LGE was measured with the 2-SD method and lowest with the 7-
SD method. Confidence intervals were broader in lower SD methods. LGE = Late gadolinium enhancement, FWHM= Full width at half maximum,
SD = Standard deviation
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justed Cox regression analyses and measurements of
the degrees of intra-and inter-rater measurement re-
producibility showed that FWHM demonstrated the high-
est technical consistency and the strongest prognostic
association with MACE amongst all LGE quantification
methods in patients with suspected myocarditis. On the
other hand, visual qualitative assessment of LGE extent
using the LGE-VPS score, represents a reliable alternative
prognosticating method with an excellent intra-and
inter-rater variability.Fig. 3 Univariable association of different semi-automated LGE (%) quantifica
LGE quantification methods, only 2-SD, 3-SD and FWHM were significantly ass
width at half maximum, SD = Standard deviation, MACE =Major adverse cardLGE extent and outcome association
As consistent with other studies including myocardial
infarction and hypertrophic cardiomyopathy patients,
different LGE extent quantification methods result in a
different extent of myocardial fibrosis, suggesting that
the different methods are not interchangeable [13, 18].
This may have practical implications: thresholds that
used lower SD cutoff may overestimate the extent of the
LGE but possess higher sensitivities in detecting abnor-
mal LGE. LGE-assessed myocardial fibrosis has been
shown to be a predictor for outcome in patients withtion methods with outcome. Comparing the different semi-quantitative
ociated with MACE. LGE = Late gadolinium enhancement, FWHM= Full
iovascular event, HR = Hazard ratio, CI = Confidence interval
Table 3 Univariable Association of Clinical and CMR for MACE
MACE
Potential Predictors HR (95% CI) p value
Baseline
Age (year) 1.03 (1.01–1.04) < 0.001
Female sex 1.60 (1.07–2.38) 0.021
Body mass index (kg/m2) 1.05 (1.02–1.08) 0.001
Referral reasons
Acute (< 2 weeks) vs. subacute
presentation (≥2 weeks)
1.87 (1.22–2.86) 0.003
History
Hypertension 1.72 (1.14–2.61) 0.011
Tobacco 1.59 (0.99–2.58) 0.057
Diabetes 2.51 (1.49–4.22) 0.001
Dyslipidemia 1.46 (0.93–2.28) 0.101
Medications
Aspirin 1.47 (1.19–1.82) < 0.001
ACE inhibitors 1.80 (1.21–2.68) 0.004
Beta-blockers 2.34 (1.55–3.51) < 0.001
Diuretics 3.03 (2.01–4.56) < 0.001
Statins 1.50 (0.95–2.35) 0.080
Insulin 3.62 (1.82–7.21) < 0.001
ECG
Abnormal ECG 1.16 (0.78–1.74) 0.455
Laboratory Testing’s
Troponin abnormal 1.01 (0.57–1.79) 0.968
Creatine-kinase abnormal 1.19 (0.62–2.29) 0.596
White blood cell count abnormal 1.79 (1.09–2.92) 0.021
CMR characteristics
LVEF (%) 0.95 (0.94–0.97) < 0.001
LVEDVi (ml/m2) 1.01 (1.00–1.02) < 0.001
LVESVi (ml/m2) 1.01 (1.01–1.02) < 0.001
LV mass index (g/m2) 1.01 (1.00–1.03) 0.021
RVEF (%) 0.95 (0.93–0.96) < 0.001
RVEDVi (ml/m2) 1.00 (0.99–1.01) 0.570
RVESVi (ml/m2) 1.02 (1.01–1.03) < 0.001
Pericardial effusion 2.31 (1.54–3.45) < 0.001
T2- weighted imaging (SIR ≥2) 2.14 (1.30–3.52) 0.003
CMR LGE quantifications methods
LGE mass (g)
- 2-SD 1.02 (1.00–1.03) 0.011
- 3-SD 1.02 (0.99–1.04) 0.064
- 4-SD 1.02 (0.99–1.05) 0.162
- 5-SD 1.01 (0.97–1.06) 0.356
- 6-SD 1.01 (0.95–1.07) 0.754
Table 3 Univariable Association of Clinical and CMR for MACE
(Continued)
MACE
Potential Predictors HR (95% CI) p value
- 7-SD 1.00 (0.92–1.09) 0.973
- FWHM 1.04 (1.02–1.06) 0.001
CMR LGE visual assessment
LGE presence 2.22 (1.47–3.35) < 0.001
LGE-VPS 1.09 (1.04–1.15) < 0.001
LGE-VTS 1.02 (1.01–1.04) < 0.001
CMR cardiac magnetic resonance imaging, LGE Late gadolinium enhancement,
HR Hazard ratio, SD Standard deviation, FWHM Full width half maximum,
MACE Major adverse cardiac events, VPS visual presence score, VTS visual
transmurality score
Gräni et al. Journal of Cardiovascular Magnetic Resonance           (2019) 21:14 Page 7 of 11myocarditis [2, 8]. In fact, we could recently demonstrate
that beside LVEF, LGE presence was associated with
MACE [9], which is in line with a study including high
risk myocarditis patients, where presence of LGE was an
independent predictor of all-cause mortality [2]. To date,
LGE extent proved to be an outcome predictor in patients
with myocardial infarction, hypertrohpic cardiomyopathy
and non-ischemic cardiomyopathy [14, 19–22]; however,
no data based on larger studies were available on progno-
sis of different LGE extent quantification methods in sus-
pected myocarditis patients.
Interestingly, in the multivariable model in our study
only FWHM and 2-SD showed an independent associ-
ation with outcome, but not using the 3 to 7-SD
methods. Compared to myocardial infarction patients
where higher SDs are used, lower SD might capture
more substrate at risk (such as edema, fibrosis and dif-
fuse scar) in myocarditis patients. Further, in the setting
of myocarditis, the areas of LGE usually demonstrate
lower signal intensity compared with LGE in patients
with myocardial infarction. Therefore, based on the
mean signal of the remote myocardium, and the differ-
ence between remote and pathological myocardium be-
ing smaller, higher SDs (especially 4 to 7-SD) might shift
the threshold for LGE far from the remote myocardium
and consequently underestimate the severity and extent
of LGE. In studies including myocardial infarction pa-
tients, where LGE is commonly found bright, and apart
from FWHM [13, 15], only thresholds higher than 2-SD
(i.e. 3-SD to 6-SD) were proposed as accurate methods
[23, 24]. However, in the setting of infarction, the differ-
ent methods were not addressed with outcome associ-
ation [25]. Interestingly our visual scoring showed
strong association with outcome. Similar results were
obtained from a small study only including 41 patients,
where LGE extent (quantified by visual transmurality
score, similar to our visual scores) remained an inde-
pendent predictor of MACE with HR 1.42 [26]. Likewise,
in another very small study from Barone-Rochette et al.
Table 4 Multivariabale Analysis of Association of LGE for MACE
Model 1 Model 2
Variables HR (95% CI) p-value Variables HR (95% CI) p-value
Age (years) 1.02 (1.01–1.04) 0.001 Age (years) 1.03 (1.01–1.04) 0.001
Sex 1.73 (1.15–2.60) 0.009 Sex 1.77 (1.17–2.65) 0.007
BMI 1.05 (1.02–1.08) 0.002 BMI 1.05 (1.02–1.08) 0.002
LVEF 0.96 (0.95–0.97) < 0.001 LVEF 0.96 (0.95–0.97) < 0.001
LGE (%, FWHM) 1.04 (1.01–1.08) 0.009 LGE (%, 2-SD) 1.02 (1.00–1.04) 0.035
Model 3 Model 4
Variables HR (95% CI) p-value Variables HR (95% CI) p-value
Age (years) 1.03 (1.01–1.04) 0.001 Age (years) 1.02 (1.00–1.04) 0.001
Sex 1.74 (1.16–2.62) 0.008 Sex 1.74 (1.12–2.61) 0.008
BMI 1.05 (1.02–1.08) 0.002 BMI 1.05 (1.02–1.08) 0.003
LVEF 0.96 (0.95–0.97) < 0.001 LVEF 0.96 (0.95–0.97) < 0.001
LGE (%, 3-SD) 1.02 (0.99–1.05) 0.117 LGE (%, 4-SD) 1.02 (0.98–1.05) 0.309
Model 5 Model 6
Variables HR (95% CI) p-value Variables HR (95% CI) p-value
Age (years) 1.02 (1.00–1.04) 0.001 Age (years) 1.02 (1.01–1.04) 0.002
Sex 1.74 (1.16–2.61) 0.008 Sex 1.70 (1.13–2.55) 0.010
BMI 1.05 (1.02–1.08) 0.002 BMI 1.05 (1.02–1.08) 0.002
LVEF 0.96 (0.95–0.97) < 0.001 LVEF 0.96 (0.95–0.97) < 0.001
LGE (VPS) 1.07 (1.02–1.13) 0.005 LGE (VTS) 1.01 (1.00–1.03) 0.087
Model 7
Variables HR (95% CI) p-value
Age (years) 1.02 (1.01–1.04) 0.005
Sex 1.79 (1.19–2.70) 0.005
BMI 1.05 (1.02–1.08) 0.001
LVEF 0.96 (0.95–0.98) < 0.001
LGE presence 1.82 (1.17–2.81) 0.008
SD Standard deviation, LGE late gadolinium enhancement, LGE-VPS LGE visual presence score, LGE-VTS LGE visual transmurality score
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plified quantitative score (SQS), similar to our LGE-VTS
score, a trend towards worse outcome in those with
higher initial SQS score (p = 0.08) could be shown [27].
It seems that visual assessment of LGE offers a rapid alter-
native for risk stratification in a diffuse or patchy disease
such as myocarditis, where in contrast to myocardial in-
farction, more myocardium at risk might be involved than
only territories subtended by a certain vessel.
Inter-rater and intra-rater variability
Some authors used manual quantification as a reference
standard to compare different quantification methods of
LGE from myocardial infarction. In our opinion, manual
contouring of LGE extent might be less consistent than
semi-automatic quantitative methods in sizing LGE of
patients with myocarditis. Compared to myocardial in-
farction, LGE from myocarditis tends to show moreblurry contours and less intense enhancement. For ex-
ample, in HCM patients presenting with rather patchy
or diffuse LGE, manual delineation had poorer inter-and
intra-rater variability compared to infarction patients
[13], proving the manual technique not to be applicable
in diseases with other LGE patterns than infarction. The
heterogeneous nature of LGE presentations leads to a
broad intra- and inter-rater variability and FWHM is
more robust than the lower SDs in our study. In the
quantification techniques associated with outcome,
inter-rater and intra-rater variability showed highest re-
producibility in the semi-automated FWHM technique,
which was also shown in the mentioned study and by
others likewise in different cardiac diseases [13, 18, 28, 29].
The FWHM method is less prone to over- or under-
estimation in myocarditis patients, where LGE extent also
might be represented by inflammation. This highlights the
fact that different LGE quantification techniques are not
Fig. 4 Reproducibility of different LGE quantification methods. Intra-rater and inter-rater variability for each LGE quantification method (calculated
as 1 - intraclass correlation coefficient [ICC]) of the different methods is lowest in visual scores and FWHM. Intra-rater variability is less marked
than inter-rater variability, as would be expected. Of the quantifications methods significantly associated with MACE, FWHM, LGE-VPS and LGE-VTS
showed the best inter- and intra-rater variability. FWHM= Full width half maximum, SD = Standard deviation; LGE-VPS = visual LGE presence score;
LGE-VTS = visual LGE transmurality score; MACE =Major adverse cardiovascular event
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since signal intensities are not comparable with those in in-
farction patients [13].
Another issue in myocarditis patients is that a high
proportion present with subepicardial fibrosis [30] and
in these cases epicardial contouring and delineation of
epicardial LGE from epicardial fat, which also presents
with a bright signal in LGE images, might pose issues
for reproducibility. Therefore, even a small change in
the epicardial contour might have a large impact on the
intra- and inter-rater variability. Consequently, our visual
scores – LGE-VPS and LGE-VTS (presence or absence of
LGE or LGE transmurality) – may be less prone to vari-
ation and showed the highest inter-rater and intra-rater
variability, which is consistent with prior literature [27].
Limitations
There are several limitations for our study. This study is a
retrospective observational design at a single center. Includ-
ing patients evaluated on both 1.5 and 3.0 Tesla systems
may potentially affect the LGE quantification; however, to
the best of our knowledge, this effect is minimal on LGE
sizing and in our multivariable model this had no signifi-
cant impact on the results. There is no clinical reference
standard for the assessment of LGE, so accuracy across the
methods cannot be determined. In that regard, we chose to
determine association with outcome as an alternative yet
clinically relevant analysis. Our initial hypothesis was to
evaluate which semi-quantitative method was best associ-
ated with the outcome. As an alternative method, we also
evaluated the visual scoring. Our observations showed that
both the visual LGE score and LGE quantitation usingFWHM demonstrated robust prognostic values and meas-
urement reproducibility, thus suggest that visual LGE score
is a reliable clinical reporting parameter whereas FWHM
be the signal intensity criteria of choice should LGE quanti-
tation be needed. Our study was not designed to determine
if image quality should be an additional factor in this deci-
sion in choosing these parameters, but our general impres-
sions is that visual LGE scoring is more consistent. Similar
to many clinical studies, details surrounding the immediate
cause of death was not possible to obtain in a minority of
patients, so we needed to rely on the use of all-cause mor-
tality. Further, the use of immunosuppressant medication
like steroids was not assessed, and therefore the influence
of such medication on the outcome cannot be evaluated in
this study. Finally, the natural course of acute myocarditis
usually is followed by a decline in inflammation and LGE
signal intensity changes during the stages of tissue healing.
Although the inclusion of the variable acute/subacute
presentation to the multivariable model did not change
the results, future prospective studies will need to de-
termine the need for optimization of the quantitative
thresholds at different clinical settings (acute, subacute,
delayed, chronic).
Conclusions
LGE presence is a strong risk marker in patients with
suspected myocarditis but quantitative methods of LGE
sizing can offer a complementary and objective risk as-
sessment. Amongst quantitative methods, LGE extent
using FWHM criteria offers the highest prognostic value
and high measurement reproducibility. Visual LGE scor-
ing method is a reliable alternative.
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